What Insurance Covers Wegovy for Weight Loss? Plans That Pay

Roughly half of Americans with commercial health insurance have had some form of Wegovy coverage in recent years, while the other half faced the full list price or hunted for alternatives. The question of what insurance covers Wegovy for weight loss matters because the list price — about $1,349 for a month’s supply as of this writing — makes meaningful access almost entirely dependent on coverage. This guide explains the patterns that predict coverage, how the major plan types differ, and, most importantly, how to verify your own plan’s rules, because coverage varies by plan and changes constantly.

How Insurance Decides Whether to Cover Wegovy

Coverage of weight-loss medications comes down to three decisions at the plan level. First, does the plan include weight-loss medications on its formulary at all? Many plans have historically excluded this entire drug category. Second, if weight-loss drugs are covered, is Wegovy specifically included, or only older, cheaper options? Third, what prior-authorization and step-therapy requirements apply before a covered prescription is approved?

Plans that cover Wegovy generally do so because the employer, insurer, or pharmacy benefit manager (PBM) has decided the clinical value — weight reduction plus, for some patients, cardiovascular risk reduction — justifies the cost. Plans that exclude it usually cite cost or prior internal reviews. Because these are business and actuarial decisions rather than federal mandates, two people with the “same” insurer can have completely different coverage.

The 2024 Cardiovascular Indication Changed the Math

A pivotal shift came when the FDA approved Wegovy (semaglutide) in 2024 for cardiovascular risk reduction in adults with established cardiovascular disease who also have obesity or overweight, based on the SELECT trial. This matters for coverage because it reframes Wegovy as more than a weight-loss drug. Some plans that excluded weight-loss medications will still cover Wegovy for the cardiovascular indication, and the added evidence has pushed some employers and PBMs to broaden access. If you have established heart disease, this indication may be your strongest path to coverage — ask your prescriber whether you qualify.

Commercial Insurance: The Big Players

Among major commercial insurers, coverage patterns look roughly like this, though every detail varies by the specific plan design. UnitedHealthcare covers Wegovy on many plan designs with prior authorization. Aetna (CVS Health) covers it on many commercial plans through CVS Caremark’s formulary. Cigna covers it on many commercial plans, though tier placement and restrictions vary. Blue Cross Blue Shield operates as a federation of state-level plans, so coverage varies significantly by state affiliate.

Humana covers Wegovy on many commercial plans but is more selective with its Medicare Advantage products. Kaiser Permanente includes Wegovy on formulary in most regions with integrated clinical management. Independent regional plans such as HealthPartners, Tufts Health Plan, and Harvard Pilgrim have similarly varied rules. The only reliable way to know whether your specific plan covers Wegovy is to check your plan’s own formulary — insurer-level generalizations are a starting point, not an answer.

Employer Self-Funded Plans

Most large employers self-fund their health plans, meaning the employer — not the insurance company — pays claims and decides what is covered, with the insurer acting as a third-party administrator. This gives employers significant control over weight-loss medication coverage. Many technology, financial-services, and pharmaceutical companies explicitly include Wegovy, while others have actively excluded weight-loss medications to control cost, including several state and municipal employee health plans that have restricted or dropped GLP-1 coverage.

Because the benefit design is the determining factor, the single most useful step for someone on an employer plan is to ask HR or the benefits department directly whether Wegovy is covered, under what conditions, and whether the cardiovascular indication is treated differently from the weight-loss indication.

What Predicts Wegovy Coverage

Several factors predict coverage. Employer size matters: larger employers are more likely to offer weight-loss drug coverage, though not always. Industry matters: technology, healthcare, and finance sectors tend to include GLP-1 coverage more often than retail, hospitality, and construction. Plan type matters: PPO plans often have broader formularies than HMO plans, with exceptions in both directions.

The age of the plan’s formulary decision also matters. Plans that reviewed their GLP-1 coverage recently are more likely to include Wegovy because the cardiovascular data strengthened the case, whereas older decisions may not reflect current evidence. Related reading: is Wegovy covered by insurance.

How to Verify Your Specific Plan

There are four reliable ways to confirm whether your insurance covers Wegovy. Log into your prescription benefit portal (often separate from your medical benefits portal) and search for “Wegovy” or “semaglutide.” Call the member-services number on the back of your card and ask specifically about Wegovy coverage, tier placement, and prior-authorization requirements. Request a copy of your plan’s formulary document. And ask your prescriber’s office to run a benefits check before writing the prescription.

The prescriber-run benefits check is often the most accurate because it uses real-time eligibility data from the PBM rather than static formulary documents that may be out of date. Most clinics can run this check in a few minutes during an appointment. Whichever route you use, ask the same follow-up: is coverage different for the cardiovascular indication than for weight loss?

Prior Authorization Requirements

Even covered plans usually require prior authorization. Common requirements include BMI documentation (30+, or 27+ with a weight-related condition), documentation of a supervised weight-loss effort (often around six months), recent bloodwork, and age verification. Some plans require a specific coordinator — often a nurse case manager — to approve the prescription.

Step therapy is another common hurdle. A plan may require a trial of cheaper options (phentermine, Contrave, or older agents) before approving Wegovy. Step-therapy denials can often be overturned with documentation of intolerance or contraindications to the required “step” drugs, so do not treat a first denial as the final word.

Medicare Coverage

Medicare Part D cannot cover Wegovy for weight loss alone. By statute, Part D excludes drugs used for weight loss. However, following the 2024 cardiovascular approval, CMS issued guidance that Part D plans may cover Wegovy for the cardiovascular risk-reduction indication in eligible patients — so a Medicare beneficiary with established heart disease and obesity/overweight may have a covered path that a beneficiary seeking weight loss alone does not. Coverage still depends on the individual plan’s formulary and prior-authorization rules.

Beyond that, a federal GLP-1 coverage demonstration has been proposed to test Medicare and Medicaid coverage of anti-obesity medications; its scope and timing have shifted, so verify its current status before relying on it. See our Medicare Wegovy coverage guide and Wegovy Medicare guide for details as they evolve.

Medicaid Coverage

State Medicaid coverage of Wegovy for weight loss remains limited but has been expanding, and it varies by state. A number of state Medicaid programs cover Wegovy for obesity under strict criteria — typically a higher BMI threshold, documented comorbidities, a trial of lifestyle intervention, and specialist oversight — while many others do not cover weight-loss drugs at all. Because state policies change and lists go out of date quickly, confirm your own state’s current Medicaid formulary rather than relying on a national roundup.

Alternatives When Insurance Says No

If your plan does not cover Wegovy for weight loss, you have several options. Novo Nordisk’s NovoCare Pharmacy offers a cash-pay program that ships Wegovy directly; self-pay pricing has come down and, as of this writing, is roughly $349 per month for standard pen doses, with a lower promotional price for the first couple of months — verify the current amount before you commit. For patients with commercial insurance whose plan covers Wegovy, the manufacturer savings offer can reduce out-of-pocket cost to as little as $25 per month (with a monthly maximum), subject to eligibility. Switching to a plan that covers Wegovy at open enrollment is another longer-term route.

Some patients switch to Zepbound (tirzepatide) if their plan covers it for weight management. Others consider compounded semaglutide, but with the shortage resolved and FDA warnings about unregulated and counterfeit products, quality and safety concerns apply — use only medications from a licensed pharmacy with a valid prescription. See our Wegovy cost guide for complete savings strategies.

Frequently Asked Questions

Does my employer have to cover Wegovy?

No. Weight-loss medication coverage is not required under the ACA or other federal mandates, so employers have full discretion to include or exclude these drugs. Ask HR about the rationale — and whether the cardiovascular indication is treated differently — if your plan excludes Wegovy.

Are ACA marketplace plans required to cover Wegovy?

No. Weight-loss drugs are not part of the ACA essential health benefits, so marketplace plans are not required to cover them. Some do include Wegovy, but you must verify coverage at the individual plan level before enrolling.

What insurance covers Wegovy for weight loss most reliably?

Large employer plans administered by UnitedHealthcare, Aetna, and Cigna tend to cover Wegovy more reliably than smaller plans, and technology and finance employers in particular often include comprehensive weight-loss coverage. Even so, the only certain answer comes from checking your specific plan.

How do I appeal a Wegovy denial?

Request the written denial and review the reason. Work with your prescriber to gather clinical documentation — BMI, comorbidities, prior weight-loss attempts, any cardiovascular disease, and a medical-necessity letter. File within your plan’s stated timeline, usually 30 to 180 days depending on plan type.

Will my coverage change next year?

Possibly. Employers and insurers can change formulary design at each annual renewal, and GLP-1 coverage has been an especially active area. Check your plan’s formulary during open enrollment each year rather than assuming last year’s coverage continues.

Your Next Step to Confirming Coverage

Verify your current plan’s Wegovy coverage through your prescription benefit portal or by calling member services, and ask specifically whether the cardiovascular indication is covered differently from weight loss. If covered, confirm the prior-authorization requirements before your prescriber submits. If not, evaluate alternative plans during open enrollment, ask about the cardiovascular indication, or look at NovoCare self-pay and manufacturer savings for immediate relief.

For broader context on public and private coverage, the healthcare policy pillar covers related programs. Understanding exactly what your plan covers — before you need the medication — can save weeks of insurance back-and-forth and potentially thousands of dollars.